Shift in Vaccine Research Focus

Earlier this month, the Trump administration announced it was terminating $500 million in mRNA vaccine research. Instead, it plans to focus on alternative methods, including a new “whole-virus” vaccine approach labeled “Generation Gold Standard.”

Dr. Jay Bhattacharya, director at the National Institutes of Health, described Generation Gold Standard as a game changer. He noted in a May news release that this approach expands vaccine protection beyond just dealing with specific strains and aims to prepare for future flu threats using modernized traditional vaccine technology.

However, many experts in vaccines and infectious diseases believe this strategy might be a misstep.

Dr. James Campbell, vice chair of the American Academy of Pediatrics Committee on Infectious Diseases, remarked that this feels like taking a step back. He mentioned that inactivated whole-virus vaccines have been around for quite some time.

The first of these vaccines, created by Louis Pasteur in the late 1800s, was an early version of the rabies vaccine.

Angela Rasmussen, a virologist from the University of Saskatchewan, added that calling this innovative is a stretch; it’s actually quite old from a vaccine perspective.

Whole-virus vaccines typically contain most parts of the virus, unlike other vaccines that target specific viral proteins to stimulate the immune response.

Dr. Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia, explained the process involves growing the virus, cleaning it, and then killing it with an inactivating agent. Some vaccines may even use live but weakened forms of the virus.

Campbell indicated that years of research have allowed scientists to identify which parts of a virus are most effective in activating the immune response—these components are called “antigens.”

An analogy might be that if the immune system acts like a bloodhound tracking intruders, newer vaccine technologies present only the most useful pieces of the intruder’s clothing. However, whole-virus vaccines provide the bloodhound with the entire wardrobe instead.

While it might seem like a better idea to use the whole virus, Campbell said that those extra bits might not enhance the immune response significantly.

For example, he pointed out that the hepatitis B vaccine, which includes just one antigen—the hepatitis B surface antigen—offers nearly 100% protection against the virus. There’s really no need for the entire virus.

Offit concurred, noting that the hepatitis B vaccine has effectively reduced infections in young children.

Campbell cited Covid-19 vaccines as further evidence. “Whole-virus Covid vaccines were available but not used in the U.S.,” he explained, adding that their general effectiveness was lower compared to the mRNA vaccines focused on the virus’s spike protein.

A study from Singapore revealed that individuals vaccinated with a whole-virus Covid vaccine were significantly more likely to get infected compared to those who received the mRNA vaccine.

He emphasized that if whole-virus vaccines had been the best approach for Covid, they would have been adopted early on in the pandemic.

Improper use of whole-virus vaccines can also be risky. Campbell pointed to the history of RSV vaccines, which, rather than providing protection, led to “antibody-dependent enhancement,” making infections worse for children vaccinated with it in the past.

This unfortunate RSV vaccine trial took place in the 1960s and set research back for decades.

Since then, RSV vaccinations have focused either on specific virus components or utilized monoclonal antibodies. The first RSV vaccine was approved in 2023.

“These newer strategies work well,” Campbell remarked. “We definitely should avoid using whole-virus killed vaccines for RSV as they can cause harm.”

Some whole-virus vaccines remain in use today, like those for hepatitis A and rabies, which include inactivated virus components. Seasonal flu vaccines also utilize whole-virus technology.

Campbell acknowledged that there could be cases in the future where whole-virus vaccines might be the best option for certain pathogens.

Searching for a Universal Flu Vaccine

Regarding whether this whole-virus method could lead to advancements in creating a universal flu vaccine—something the Department of Health and Human Services hinted at—Campbell mentioned it’s feasible if the vaccines were genetically engineered to incorporate multiple flu strain antigens. However, he added that it’s not particularly about the whole-virus technique itself.

He stated, “If it’s just whole-virus with one strain, that’s already what we currently do.”

Emily Hilliard, HHS press secretary, expressed that Generation Gold Standard represents a vital step toward improving America’s pandemic preparedness.

She stated that the BPL vaccine platform, developed entirely by government scientists and free from industry influence, could provide comprehensive protection against various flu viruses and possibly coronaviruses, along with potential benefits in stopping outbreaks at their source.

Developing a universal flu vaccine has long been a goal for scientists, ideally providing extended protection without the need for yearly updates due to the virus’s rapid mutation.

“There are many different approaches being explored,” Campbell mentioned, cautioning against focusing solely on an older technology that has previously failed to achieve a universal flu vaccine. “I think it risks putting all our eggs in one basket and hampers progress.”

Offit warned that cutting research funding for mRNA vaccines might be detrimental if another pandemic arises.

“If a serious situation, like a bird flu outbreak happens, we won’t be prepared,” he pointed out, noting that mRNA technology allows for quicker production compared to whole-killed virus vaccines.

Rasmussen added that transitioning to a whole-virus vaccine could take a lot longer, as it would require substantial virus growth and inactivation steps.

Other technologies, like protein subunit or mRNA vaccines, can be synthesized without needing to grow any virus, making them more adaptable for new strains.

Offit revealed that some of the research cut from the $500 million funding withdrawal included studies on the mRNA technology’s value for addressing bird flu.

Ultimately, Campbell stressed that scientific inquiry should guide decisions, rather than enforcing directives that limit scientists’ capabilities.

“It’s the details that matter, not just generalized statements about which vaccine platforms are appropriate,” he said.

Various platforms exist for vaccine development, each tested for their unique features. Over time, some may prove more effective, becoming the focus of further research.

“In vaccinology, we try to figure out what works based on foundational science, immunology, and disease models before moving to human studies. It’s about comparing immune responses, safety, and efficacy—not just sweeping statements,” he concluded.